Protocol Paper: a Multi-center, Double-blinded, Randomized, 6-month, Placebo-controlled Study Followed by 12-month Open Label Extension to Evaluate the Safety and Efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2022 Jun 1

PMID 35650602

Authors

Bernard J Smilde

Clemens Stockklausner

Richard Keen

Andrew Whittaker

Alex N Bullock

Annette von Delft

Natasja M van Schoor

Paul B Yu

E Marelise W Eekhoff

Affiliations

Soon will be listed here.

Abstract

Background: Fibrodysplasia Ossificans Progressiva (FOP) is a genetic, progressive and devastating disease characterized by severe heterotopic ossification (HO), loss of mobility and early death. There are no FDA approved medications. The STOPFOP team identified AZD0530 (saracatinib) as a potent inhibitor of the ALK2/ACVR1-kinase which is the causative gene for this rare bone disease. AZD0530 was proven to prevent HO formation in FOP mouse models. The STOPFOP trial investigates the repositioning of AZD0530, originally developed for ovarian cancer treatment, to treat patients with FOP.

Methods: The STOPFOP trial is a phase 2a study. It is designed as a European, multicentre, 6-month double blind randomized controlled trial of AZD0530 versus placebo, followed by a 12-month trial comparing open-label extended AZD0530 treatment with natural history data as a control. Enrollment will include 20 FOP patients, aged 18-65 years, with the classic FOP mutation (ALK2 R206H). The primary endpoint is objective change in heterotopic bone volume measured by low-dose whole-body computer tomography (CT) in the RCT phase. Secondary endpoints include F NaF PET activity and patient reported outcome measures.

Discussion: Clinical trials in rare diseases with limited study populations pose unique challenges. An ideal solution for limiting risks in early clinical studies is drug repositioning - using existing clinical molecules for new disease indications. Using existing assets may also allow a more fluid transition into clinical practice. With positive study outcome, AZD0530 may provide a therapy for FOP that can be rapidly progressed due to the availability of existing safety data from 28 registered clinical trials with AZD0530 involving over 600 patients.

Trial Registration: EudraCT, 2019-003324-20. Registered 16 October 2019, https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003324-20/NL .

Clinicaltrials: gov , NCT04307953 . Registered 13 March 2020.

Citing Articles

BMP-9 mediates fibroproliferation in fibrodysplasia ossificans progressiva through TGF-β signaling.

Zhao C, Inada Y, Motoike S, Kamiya D, Hino K, Ikeya M EMBO Mol Med. 2024; 17(1):112-128.

PMID: 39627568 PMC: 11729865. DOI: 10.1038/s44321-024-00174-3.

[F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders.

Zwama J, Rosenberg N, Verheij V, Raijmakers P, Yaqub M, Botman E Biomolecules. 2024; 14(10).

PMID: 39456213 PMC: 11505869. DOI: 10.3390/biom14101276.

Structural and molecular imaging-based characterization of soft tissue and vascular calcification in hyperphosphatemic familial tumoral calcinosis.

Sheppard A, Paravastu S, Farhadi F, Donnelly E, Hartley I, Gafni R J Bone Miner Res. 2024; 39(9):1327-1339.

PMID: 39046425 PMC: 11371904. DOI: 10.1093/jbmr/zjae115.

Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.

Haviv R, Zeitlin L, Moshe V, Ziv A, Rabinowicz N, De Benedetti F Rheumatology (Oxford). 2024; 63(9):2597-2604.

PMID: 38733591 PMC: 11371373. DOI: 10.1093/rheumatology/keae255.

Dual Drug Repurposing: The Example of Saracatinib.

Ramos R, Vale N Int J Mol Sci. 2024; 25(8).

PMID: 38674150 PMC: 11050334. DOI: 10.3390/ijms25084565.

References

Song G, Kim H, Woo K, Baek J, Kim G, Choi J . Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem. 2010; 285(29):22542-53. PMC: 2903413. DOI: 10.1074/jbc.M109.094557. View

Frail D, Brady M, Jane Escott K, Holt A, Sanganee H, Pangalos M . Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat Rev Drug Discov. 2015; 14(12):833-41. DOI: 10.1038/nrd4707. View

Hsiao E, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo R . Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2018; 85(6):1199-1207. PMC: 6533500. DOI: 10.1111/bcp.13777. View

Ferreira C . The burden of rare diseases. Am J Med Genet A. 2019; 179(6):885-892. DOI: 10.1002/ajmg.a.61124. View

Eekhoff E, Botman E, Netelenbos J, de Graaf P, Bravenboer N, Micha D . [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva. Bone. 2017; 109:143-146. DOI: 10.1016/j.bone.2017.08.012. View

Xie Z, Yang X, Duan Y, Han J, Liao C . Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. J Med Chem. 2021; 64(3):1283-1345. DOI: 10.1021/acs.jmedchem.0c01511. View

Braun M, Farag-El-Massah S, Xu K, Cote T . Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010; 9(7):519-22. DOI: 10.1038/nrd3160. View

Griggs R, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J . Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2008; 96(1):20-6. PMC: 3134795. DOI: 10.1016/j.ymgme.2008.10.003. View

Pignolo R, Bedford-Gay C, Liljesthrom M, Durbin-Johnson B, Shore E, Rocke D . The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. J Bone Miner Res. 2016; 31(3):650-6. PMC: 4829946. DOI: 10.1002/jbmr.2728. View

10.

Chan A, Tetzlaff J, Gotzsche P, Altman D, Mann H, Berlin J . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346:e7586. PMC: 3541470. DOI: 10.1136/bmj.e7586. View

11.

Hatsell S, Idone V, Wolken D, Huang L, Kim H, Wang L . ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015; 7(303):303ra137. PMC: 6164166. DOI: 10.1126/scitranslmed.aac4358. View

12.

Pignolo R, Baujat G, Brown M, De Cunto C, Di Rocco M, Hsiao E . Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019; 14(1):98. PMC: 6499994. DOI: 10.1186/s13023-019-1068-7. View

13.

Wakap S, Lambert D, Olry A, Rodwell C, Gueydan C, Lanneau V . Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2019; 28(2):165-173. PMC: 6974615. DOI: 10.1038/s41431-019-0508-0. View

14.

Wu P, Nielsen T, Clausen M . FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015; 36(7):422-39. DOI: 10.1016/j.tips.2015.04.005. View

15.

Williams E, Bagarova J, Kerr G, Xia D, Place E, Dey D . Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021; 6(8). PMC: 8119212. DOI: 10.1172/jci.insight.95042. View

16.

Gregson C, Hollingworth P, Williams M, Petrie K, Bullock A, Brown M . A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone. 2010; 48(3):654-8. PMC: 3160462. DOI: 10.1016/j.bone.2010.10.164. View

17.

Scherman D, Fetro C . Drug repositioning for rare diseases: Knowledge-based success stories. Therapie. 2020; 75(2):161-167. DOI: 10.1016/j.therap.2020.02.007. View

18.

Kaplan F, Zasloff M, Kitterman J, Shore E, Hong C, Rocke D . Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010; 92(3):686-91. PMC: 2827822. DOI: 10.2106/JBJS.I.00705. View

19.

Pignolo R, Hsiao E, Baujat G, Lapidus D, Sherman A, Kaplan F . Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021; 16(1):350. PMC: 8340531. DOI: 10.1186/s13023-021-01983-2. View

20.

Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas M, Villaverde-Hueso A, Gamir-Gamir M, Alonso-Ferreira V . Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012; 51(4):748-55. DOI: 10.1016/j.bone.2012.07.002. View